Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma.

ABSTRACT:

Background & aims

Hepatocellular carcinoma (HCC) has high potential for recurrence, even in curative operative cases. Although several molecular-targeting drugs have been applied to recurrent HCC, their effectiveness has been limited. This study therefore aims to develop novel cancer drugs through protein methylation.

Methods

We investigated the role of KDM5B/JARID1B, a member of JmjC histone demethylase, in HCC. Expression profiles of KDM5B were examined by immunohistochemical analysis in 105 HCC clinical tissue samples. To examine functional effects of KDM5B using HCC cell lines, we performed loss-of-function analysis treated with KDM5B-specific small interfering RNAs (siKDM5B).

Results

All HCC cases were divided into KDM5B-positive expression group (n=54) and negat

SUBMITTER: Shigekawa Y 

PROVIDER: S-EPMC6188148 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature